Business Context and Reporting Period
This Form 8-K is a current report filed by Graybug Vision, Inc. (not Calcimedica, Inc.) on March 5, 2021. The registrant is a Delaware corporation with its principal executive offices in Redwood City, California, and its common stock trades on the Nasdaq Global Market under the symbol "GRAY". The filing is intended to disclose material non-public information regarding results of operations or financial condition pursuant to Item 2.02.
Key Financial Metrics
The provided filing text does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a cover sheet referencing a press release (Exhibit 99.1) dated March 4, 2021, which contains the actual financial details. Consequently, no financial metrics can be extracted from this text alone.
Material Changes
The filing indicates that a public announcement was made on March 4, 2021, disclosing material non-public information regarding the registrant's results of operations or financial condition for a completed quarterly or annual fiscal period. The specific nature of these changes is not detailed in the Form 8-K text itself but is contained within the attached press release.
Guidance, Outlook, and Risks
The registrant identifies itself as an emerging growth company under Rule 405 of the Securities Act of 1933. The filing text does not provide specific management commentary, forward-looking guidance, risk factors, or contingencies. These elements are presumed to be included in the referenced press release exhibit.
Investor Verification Checklist
- Verify the discrepancy between the requested company name (Calcimedica, Inc.) and the actual registrant (Graybug Vision, Inc.).
- Review Exhibit 99.1 (Press Release dated March 4, 2021) to obtain the specific financial results and operational updates referenced in this filing.
- Confirm the fiscal period covered by the results of operations mentioned in the press release.
- Check for any subsequent amendments or filings that may provide the detailed financial statements referenced in Item 9.01.